Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma
Authors:
- Rana RaisRRRana Rais
- Andrej JančaříkAJAndrej Jančařík
- Michael NedelcovychMNMichael Nedelcovych
- Jesse AltJAJesse Alt
- Judson EnglertJEJudson Englert
- Camilo RojasCRCamilo Rojas
- Anne LeALAnne Le
- Amira ElgogaryAEAmira Elgogary
- Jessica TanJTJessica Tan
- Kelly PateKPKelly Pate
- 6 September 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (18) , 8621-8633
Abstract
The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON, 1) has shown robust anticancer efficacy in preclinical and clinical studies, but its development was halted due to marked systemic toxicities. Herein we demonstrate that DON inhibits glutamine metabolism and provides antitumor efficacy in a murine model of glioblastoma, although toxicity was observed. To enhance DON’s therapeutic index, we utilized a prodrug strategy to increase its brain delivery and limit systemic exposure. Unexpectedly, simple alkyl ester-based prodrugs were ineffective due to chemical instability cyclizing to form a unique diazo-imine. However, masking both DON’s amine and carboxylate functionalities imparted sufficient chemical stability for biological testing. While these dual moiety prodrugs exhibited rapid metabolism in mouse plasma, several provided excellent stability in monkey and human plasma. The most stable compound (5c, methyl-POM-DON-isopropyl-ester) was evaluated in monkeys, where it achieved 10-fold enhanced cerebrospinal fluid to plasma ratio versus DON. This strategy may provide a path to DON utilization in glioblastoma multiforme patients.Keywords
Funding Information
- Ústav organické chemie a biochemie AV CR, v.v.i. (RVO 61388963)
- Maryland Technology Development Corporation
This publication has 42 references indexed in Scilit:
- Tumor Metabolism of Malignant GliomasCancers, 2013
- Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase InhibitorsJournal of Medicinal Chemistry, 2012
- Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B CellsCell Metabolism, 2012
- Glutamine addiction: a new therapeutic target in cancerTrends in Biochemical Sciences, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Metabolism and action of amino acid analog anti-cancer agentsPharmacology & Therapeutics, 1990
- Studies on prodrugs. IV. Preparation and characterization of N-(5-substituted 2-oxo-1,3-dioxol-4-yl)methyl norfloxacin.Chemical and Pharmaceutical Bulletin, 1984
- SUPPRESSION OF URIC ACID SYNTHESIS IN THE GOUTY HUMAN BY THE USE OF 6-DIAZO-5-OXO-L-NORLEUCINE*Journal of Clinical Investigation, 1960
- 6-Diazo-5-oxo-L-norleucine, A New Tumor-inhibitory Substance. II.1 Isolation and Characterization2Journal of the American Chemical Society, 1956